Approximately 25-30% of patients with non-small cell lung cancer (NSCLC) present with early stage disease and undergo surgery with curative intent.Despite complete tumor resection, many of these patients will develop systemic relapses with or without local relapses and will eventually die from the disease.Systemic relapses occur due to the presence of micro-metastatic disease at the time of surgery. In order to treat these micro-metastases in an early stage, adjuvant chemotherapy following complete tumor resection has been studied.A meta-analysis of early trials indicated a trend towards improved survival for adjuvant platinum-based chemotherapy (1) and led to re-evaluation of adjuvant chemotherapy in clinical trials on large patient populations (2-8). Several of these trials demonstrated that adjuvant chemotherapy improves survival (3-6).The survival benefit was then further confirmed in a meta-analysis that included all five cisplatin-based trials (9). Thus adjuvant chemotherapy has been established for patients with stages II and III. Here we summarize the current status of adjuvant chemotherapy in patients with completely resected NSCLC.

Background: lung cancer is characterized by the uncontrolled growth of cells in the lung tissue. The purpose of the present study was to investigate the expression of MUC1 mRNA and CK19 mRNA biomarkers in patients with non-small-cell lung carcinoma (NSCLC). Materials and Methods: In this case-control research, thirty samples of cancer blood, thirty samples of cancer tissue, and the same number of healthy samples were prepared. Samples were collected and RNA was extracted, then cDNA was made and gene expression was measured using Real-Time PCR. Results: Among non-small-cell lung carcinoma patients, the MUC1 mRNA marker was positive for 19 individuals while in the healthy group, it was reported positive in 5 out of 30 individuals. In the patients' group, the CK19 mRNA marker was positive for 16 individuals while in the healthy group, in 6 out of 30 individuals. Conclusion: The MUC1 mRNA and CK19 mRNA as lung cancer tumor markers were reliable and sensitive,however, further studies are recommended.